SUBSCRIBE
SUBSCRIBE
Dan Samorodnitsky

Dan Samorodnitsky

News Editor

Dan Samorodnitsky is the news editor at BioSpace. He has a decade of experience covering biotech, genetics and medicine. Before coming to BioSpace he was an editor at Drug Discovery News and Massive Science, and his writing has appeared in outlets such as Quanta, STAT, GROW and many others. He is based in Minneapolis. You can reach him at dan.samorodnitsky@biospace.com.

Creative picture image collage banner of guy worker jump from financial charts determined company success.
Earnings
Insmed Jumps on ‘Blowout’ Sales Beat for Bronchiectasis Drug Brinsupri
Insmed’s freshly approved lung condition drug soared past sales expectations for 2025, netting $144.6 million in its first full quarter of sales.
January 9, 2026
 · 
1 min read
 · 
Dan Samorodnitsky
Retro styled image of a set of different colorful alarm clocks
Complete response letters
Vanda Slides After FDA Again Rejects Hetlioz For Jet Lag
The DC-based biopharma disputed the FDA’s conclusions regarding the data provided in its supplemental application for Hetlioz and promised to keep pushing for an approval.
January 8, 2026
 · 
2 min read
 · 
Dan Samorodnitsky
Focus on the path, Businessman running on his own track
Rare diseases
Crinetics Advances Potential Neurocrine Competitor With Fresh Data and Money
The company announced a $350 million public offering on Monday shortly after revealing positive Phase II results for its investigational congenital adrenal hyperplasia drug, with hopes to one day compete with Neurocrine’s Crenessity.
January 7, 2026
 · 
2 min read
 · 
Dan Samorodnitsky
Podcast
Novo Launches Oral Obesity Pill, Lilly Targets Lofty Revenue, FDA and M&A in Focus
Novo Nordisk follows Christmas oral Wegovy approval with quick launch; Eli Lilly is headed for $94.3 billion in annual revenue by 2027, analysts predict; nine more pharmas strike Most Favored Nation deals but half remain unsigned; experts call for stability and rare disease action at FDA, and all eyes are on M&A ahead of the J.P. Morgan Healthcare conference next week.
January 7, 2026
 · 
2 min read
 · 
Heather McKenzie
3D Illustration of unlucky business man under rain, surreal concept
Vaccines
Vaccine Investors Keep Their Heads Down as Trump Cuts Shot Schedule
The US dramatically altered its recommendations for a series of vaccines, which drive billion-dollar earnings for giants like Merck and Pfizer.
January 6, 2026
 · 
3 min read
 · 
Dan Samorodnitsky
Novo Nordisk's logo on the facade of its building in Germany
Obesity
Novo Unveils Oral Wegovy in the US, With Out-of-Pocket Prices at $149 Per Month
After getting the crucial first-mover advantage with an FDA approval for a weight loss pill, Novo Nordisk looks to win the market before rival Lilly can arrive with its own oral option for obesity.
January 5, 2026
 · 
2 min read
 · 
Dan Samorodnitsky
Digital overload and its impact on the human brain, showcasing fragmented thoughts, information overload. Abstract design art collage. Social media digital addiction, mental health, stress, anxiety
Business
BioSpace Editors’ Top 5 Biggest News Stories of the Year
Pfizer and Metsera, Sarepta and uniQure made the list with dramatic tales. The other two spots went to the regulatory challenges facing biopharma under the new administration, especially in the vaccines sector.
December 22, 2025
 · 
10 min read
 · 
Annalee Armstrong
Digital compass. Business strategic explorer, Vision crisis, Mission path, Agency creative, Digital strategy, Market decision, Achievement strategy, Financial stock, Company vision concepts
FDA
FDA Policy Tracker: 2025 Was a Year of Change
Policy initiatives have come fast and furious at the FDA this year. While guidances on rare diseases and vaccines have consumed most of the ink, policy shifts aimed at improving FDA efficiencies and reshoring U.S. manufacturing also got some attention. Here, BioSpace rounds up more than a dozen initiatives relevant to the biopharma industry.
December 22, 2025
 · 
13 min read
 · 
Heather McKenzie
3D illustration Cloud with coins hanging for business and money saving concept, Minimal creative scene 3d render.
Rare diseases
Kyowa Kirin Could Get Windfall From Updated Newborn Screening Recommendations
A report from analysts at Jefferies suggested that new screenings for metachromatic leukodystrophy and Duchenne muscular dystrophy could bump sales of the gene therapy Libmeldy by more than $100 million.
December 19, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
Sep 21, 2020 Brisbane / CA / USA - BioMarin headquarters in Silicon Valley; BioMarin Pharmaceutical Inc. is an American biotechnology company
Mergers & acquisitions
BioMarin Pumps Up Revenue Goals With $4.8B Amicus Purchase
BioMarin Pharmaceutical has faced a rocky road, promising and then backing off revenue targets and cutting assets that have underperformed. But Amicus’ rare disease portfolio is already bringing in $600 million annually.
December 19, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
Pulsing heart collage illustration, sign of life. Isolated human heart organ with glowing red line surrounding, black and white
Cardiovascular disease
Cytokinetics’ Moment of Truth: Can Aficamten Take On BMS in Hypertrophic Cardiomyopathy?
After 27 years in business, Cytokinetics hopes to pit its own cardiac myosin inhibitor against one it initially developed—now owned by Bristol Myers Squibb—in a market worth billions. Aficamten has a PDUFA date of Dec. 26.
December 19, 2025
 · 
5 min read
 · 
Dan Samorodnitsky
Facade of Novo Nordisk's office in Fremont, California
Obesity
Novo Nordisk Files Combo Obesity Drug CagriSema For FDA Approval
The filing comes as Novo fights tooth-and-nail with rival Lilly to regain its footing at the top of the weight loss market.
December 18, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
Cambridge, USA - 16 August 2024. View of Moderna office entrance with logo sign, Biotechnology industry
influenza
Moderna Scores $54 Million From CEPI To Fund Bird Flu Vaccine
The money replaces a small portion of a contract Moderna lost when the Department of Health and Human Services canceled $760 million in backing to develop the vaccine, called mRNA-1018.
December 18, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
2006 James Gathany Captured by James Gathany, Centers for Disease Control's biomedical photographer, this 2006 image depicted the exterior of the new "Tom Harkin Global Communications Center", otherwise known as Building 19, located on the organization's Roybal Campus in Atlanta, Georgia. The facility houses the CDC's Information Center/Library, auditoria and meeting halls, which are used to accommodate in-house staff meetings, and national/international conferences hosted by the CDC, and the National Center for Health Marketing's, Division of Creative Services, which includes a full service television broadcast facility. The exhibit area currently features the "Global Symphony", the first of several permanently installed exhibitions, and changing exhibitions that focus on a variety of public health topics. The exhibits in the Center are self-guided, and require no advance reservations. Additional curriculum-based exhibits and programming will be added in the future. Tom Harkin Global Communications Center Exhibit Area Centers for Disease Control and Prevention - 1600 Clifton Road, N.E., Atlanta, Georgia 30333 - Hours: Monday – Friday, 9 am – 5 pm, except for federal holidays Admission is free - Government-issue photo ID is required for entry. Please note that CDC is a working federal facility and as such does not provide public tours of its campus and laboratories. - For more information please call 404-639-0830.
Vaccines
CDC Formally Adopts Delayed Hepatitis B Vaccine Dose
The CDC accepted the recommendation of its advisory committee that the shot be delayed for many patients until they are at least two months of age due to safety concerns. The CDC itself has said the vaccine is safe and effective.
December 17, 2025
 · 
4 min read
 · 
Tristan Manalac
Podcast
Lilly’s Triple Triumph, Prasad’s COVID Error, J&J’s Surprise Voucher, M&A Targets
Eli Lilly’s retatrutide exceeds expectations in Phase III, capping off a sparkling 2025 for the obesity titan; an internal FDA safety review finds no confirmed pediatric deaths caused by COVID-19 vaccines, and Commissioner Marty Makary says no black box warning will be attached to the shots; and BioSpace looks at six biotechs that could be pharma’s next buy.
December 17, 2025
 · 
2 min read
 · 
Heather McKenzie
Load More